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Abstract   (100-150 words, max 250) 40 
While philosophers in ancient times had many ideas for the cause of contagion, the 41 
modern study of infective agents began with Fracastoro’s 1546 proposal that invisible 42 
“spores” spread infectious disease.  However, firm categorization of the pathogens of the 43 
natural world would need to await a mature germ theory that would not arise for three 44 
hundred years.  In the 19th century, the earliest pathogens described were bacteria and 45 
other cellular microbes.  By the close of that century, the work of Ivanovsky and 46 
Beijerinck introduced the concept of a virus, an infective particle smaller than any known 47 
cell.  Extending into the early-mid 20th century there was an explosive growth in 48 
pathogenic microbiology, with a cellular or viral cause identified for nearly every 49 
transmissible disease.  A few occult pathogens remained to be discovered, including the 50 
infectious proteins (prions) proposed by Prusiner in 1982.  This review discusses the 51 
prions identified in mammals, yeasts, and other organisms, focusing on the amyloid-52 
based prions.  I discuss the essential biochemical properties of these agents and the 53 
application of this knowledge to diseases of protein misfolding and aggregation, as well 54 
as the utility of yeast as a model organism to study prion and amyloid proteins that affect 55 
human and animal health.  Further, I summarize the ideas emerging out of these studies 56 
that the prion concept may go beyond proteinaceous infectious particles and that prions 57 
may be a subset of proteins having general nucleating or seeding functions involved in 58 
non-infectious as well as infectious pathogenic protein aggregation. 59 
Key words: prion, amyloid, PrP, human, yeast, Sup35, [PSI+], Ure2, [URE3], nucleation, 60 
propagation, maintenance, composition, amino acids, bioinformatics, prionoid, quasi-61 
prion 62 
1. Introduction 63 
As long as there have been humans, curing and preventing illness in humankind has been 64 
a goal that crosses all cultural and geographic boundaries.  Key to any real understanding 65 
of how to heal the sick was careful study of illness, identification of true causes of 66 
diverse types of sickness, and experiments to assess methods of cure and prevention.  67 
This article explores the historical development of infectious disease etiology (section 2) 68 
culminating in the proposal of a purely protein-based infectious agent, the prion.  69 
Scientific evidence for the existence of infectious prions in animals and in yeasts and 70 
other species is presented in section 3.  While a subset of proteins were identified with 71 
this unusual pathogenicity and transmissibility, the essential question of why only some 72 
proteins displayed this behavior was the next big question, addressed in section 4.  Some 73 
answers of what makes a protein a prion grew out of basic structural characterization of 74 
prions, examining their amyloid structure, and further experiments in animals and yeasts 75 
have begun to fine-tune that understanding.  Finally, this growing understanding of prions 76 
has had implications for non-infectious protein aggregation diseases in humans and 77 
animals and has led to an enlargement of the prion concept, discussed in section 5. 78 
2. Pathogens and the Emergence of the Prion Hypothesis 79 
2.1 The causative agents of infectious disease 80 
Diseases of antiquity such as leprosy and plague left indelible marks on cultures and 81 
civilizations but also had no known and agreed-upon cause.  Some blamed supernatural 82 
forces, others vapors and miasmas, and still others diet, living conditions, and 83 
atmospheric climate.  The ancient Greek physician Galen, working in the 2nd century CE 84 
from the medical principles of Hippocrates and others, was the primary proponent of the 85 
idea of diseases caused by miasma (“pollution”) or poor quality air.  In 1546, Girolamo 86 
Fracastoro, the eminent Venetian physician, published his work De Contagione et 87 
Contagiosis Morbis promulgating the idea of “spores,” directly transmitted (contagion) 88 
and also distantly transmitted, and fomites ‘not themselves corrupt’ indirectly spreading 89 
these seeds of disease.  This work was published during the time he was serving as the 90 
elected physician of the Council of Trent and proved to be an influential counterpoint to 91 
the prevailing notion of miasmas.  However, Galen’s miasma theory of disease would not 92 
be fully supplanted in the minds of physicians and scientists until the last years of the 19th 93 
century with the advent of the germ theory of disease (Table 1). 94 
 95 
2.2 Cellular causes of infectious diseases 96 
A medieval Dutch draper who wanted to see his threads better, Antonie van 97 
Leeuwenhoek, became the celebrated lens and microscope maker that introduced the 98 
world to the first observations of microscopic organisms.  Beginning in 1673, van 99 
Leeuwenhoek’s 190 letters to the Royal Society described observations of the first cells 100 
that he termed animalculum (‘very small animals’).  In the course of his work, van 101 
Leeuwenhoek noted not only the first unicellular organisms (protists) but also the first 102 
bacteria and subcellular structures.  The English scientist Robert Hooke coined the term 103 
cell in his 1665 book Micrographia to describe the individual compartments in cork and 104 
living plants that were analogous to the animalcules of van Leeuwenhoek. 105 
Although microscopic cells and microbes were known from the 17th century, for nearly 106 
two hundred years after van Leeuwenhoek and Hooke doctors and scientists saw no 107 
connection between the cellular microbes and disease, even in some cases postulating 108 
that organisms found in diseased tissues were the effect, rather than the cause, of injury.  109 
A ‘germ theory’ arose in the 19th century, connecting the presence of infectious 110 
organisms with disease. Agostino Bassi (1838, silkworm disease) gained rapid 111 
acceptance for his work but Ignaz Semmelweis (1847-1861, childbed or puerperal fever) 112 
met with substantial resistance for a germ theory of disease.   113 
The French chemist Louis Pasteur firmly established the germ theory of disease with his 114 
experiments demonstrating a microbial cause for fermentation, disproving spontaneous 115 
generation, developing ‘pasteurization,’ and linking particular silkworm diseases to 116 
microbes (1857-1870).  German scientist Ferdinand Cohn soon formally described and 117 
classified the Bacteria (1875).  Visiting Cohn at Breslau, physician Robert Koch 118 
demonstrated the use of pure cultures of anthrax bacilli to cause the illness in previously 119 
healthy animals (1876 with refinements continuing in later years).  While developing his 120 
famous postulates for connecting specific microorganisms with specific diseases, Koch in 121 
the 1880s made several other connections between disease-causing or pathogenic 122 
organisms and their specific organic diseases, notably cholera and tuberculosis.  Many 123 
other scientists and physicians contributed their observations to the growing body of 124 
evidence that supported the germ theory of disease. 125 
 126 
2.3 Non-cellular causes of disease in animals 127 
Building on the work of Pasteur, Koch, and others in the mid-late 19th century, the 128 
microbiological agents responsible for the great diseases of antiquity were, one after 129 
another, systematically identified.  As described, the first pathogenic agents identified 130 
were those in which the organisms in question could be readily observed under the 131 
microscope, such as Pasteur’s discovery of a microsporidian parasite as the cause of the 132 
pébrine disease of silkworms and Koch’s discovery of the bacterium Bacillus anthracis 133 
as the cause of anthrax.   134 
However, some diseases stymied the efforts of even the giants of the new fields of 135 
bacteriology and microbiology.  Although Pasteur successfully developed a rabies 136 
vaccine in 1886, he could not identify the causative agent, speculating that it was too 137 
small to be visible through the use of the microscope.  Another French microbiologist, 138 
Charles Chamberland, developed a special porcelain filter that excluded anything as large 139 
as the known bacteria (1884).  The Chamberland Filter proved important for extending 140 
the germ theory of disease beyond the cellular parasites, protists, and bacteria.  Russian 141 
scientist Dmitri Ivanovsky used a Chamberland Filter to remove bacteria and isolate the 142 
tobacco mosaic virus (1892) although it was not initially perceived to be anything other 143 
than a bacterial toxin.  The Dutch microbiologist Martinus Beijerinck in 1898 realized 144 
that Ivanovsky’s filtrate actually contained a new infectious agent that he referred to both 145 
as a contagium vivum fluidum  (‘living fluid germ’) and as a virus (‘slimy poison liquid’).  146 
In the same year, Friedrich Loeffler and Paul Frosch discovered the first animal virus 147 
(aphthovirus for foot-and-mouth disease) using a similar filter.  148 
The composition of viruses was not immediately understood.  American virologist 149 
Wendell Stanley, working with Ivanovsky’s filtered agent, now known as tobacco mosaic 150 
virus (TMV), successfully crystallized it, proving it was not a liquid as Beijerinck has 151 
proposed.  However, Stanley initially believed that TMV contained only protein and only 152 
later realized the concomitant presence of a nucleic acid (Stanley 1935; Cohen, SS 1942).  153 
The scientific community had not yet firmly settled on nucleic acid as the particle of 154 
heredity by this time, but evidence was accumulating. 155 
Since Friedrich Miescher’s 1869 discovery of the nuclein or nucleic acid found in nuclei 156 
of eukaryotic cells, scientists had been probing its structure.  Phoebus Levene’s 1919 157 
tetranucleotide hypothesis of nucleic acid structure (Levene 1919) held sway in the 158 
scientific community for decades, suggesting nucleic acid would be a poor informational 159 
molecule and that therefore protein would be a superior basis for the particles of heredity.  160 
When Frederick Griffith’s 1928 pneumococcal ‘transforming principle’ (molecule of 161 
heredity) (Griffith 1928) was proven to be nucleic acid (Avery et al. 1944), the 162 
composition and structure of viral genetic information also became a point of intense 163 
interest.  It was Alfred Hershey and Martha Chase, working with bacteriophage (bacterial 164 
virus) T2, who demonstrated that the nucleic acid portion of the virus was its hereditary 165 
material as well (Hershey & Chase 1952).   166 
By this time, a host of viruses had been identified as the causative agents of plant and 167 
animal diseases, complementing the many cellular pathogens identified in the 19th and 168 
early 20th centuries.  By the mid-20th century, the majority of the pathogenic agents 169 
causing known infectious diseases had been identified (Brachman 2003).  All of these 170 
agents were cellular or viral in nature. 171 
   172 
2.4 Unusual disease traits in animals 173 
Despite success with identifying many cellular and viral pathogens, the cause of a few 174 
rare diseases remained stubbornly difficult to pinpoint.   175 
One of these diseases was a condition known as scrapie observed in Merino sheep in 176 
Spain in 1732 (Table 2, top).  This disease, in which sheep obsessively scrape themselves 177 
against trees, fence posts, and other obstacles, also manifests a variety of symptoms 178 
affecting the nervous system:  altered gait, lip smacking, and convulsions.  Although 179 
clearly infectious within flocks, long and variable incubation periods made determination 180 
of etiology difficult.  No virus or cellular cause had been identified as a cause of scrapie, 181 
but it had been hypothesized that the disease was caused by a ‘slow virus,’ an 182 
exceptionally slow-to-propagate virus with a long incubation period (Cuille & Chelle 183 
1938a; Sigurðsson 1954). 184 
Human diseases of unknown etiology were found with similarities to scrapie (Table 2, 185 
bottom).  A human neurological disorder that would come to be known as Creutzfeldt-186 
Jakob disease (CJD) was identified in 1920 (Creutzfeldt 1920; Jakob 1921).  Another 187 
human disease found among the Fore tribe of Papua New Guinea, called kuru or the 188 
‘laughing disease,’ was brought to the attention of the scientific community in 1959 189 
(Gajdusek & Zigas 1959; Klatzo et al. 1959). Immediately, the similarities in these 190 
diseases were noted (Hadlow 1959; Klatzo et al. 1959) and it was postulated that all of 191 
them were infectious (like scrapie) and due to a slow virus.  Later experiments proved 192 
their transmissible nature and these diseases came to be known as transmissible 193 
spongiform encephalopathies (TSEs) on the basis of their essential neuroanatomic effect 194 
of producing tiny holes in the brain cortex of affected individuals (Fig. 1).   195 
 196 
2.5 Non-Mendelian inheritance of characters in the baker’s yeast 197 
In 1965, yeast geneticist Brian Cox traced and described an unusual trait he called [ψ+] 198 
(now written as [PSI+]) in the baker’s yeast Saccharomyces cerevisiae.  The [PSI+] trait 199 
was a suppressor of a super-suppressor of stop codons, a gene now known as SUP35. 200 
What made the trait more puzzling was that in Cox’s meticulous studies of inheritance, 201 
[PSI+] did not obey Mendelian principles of inheritance (Cox 1965; reviewed in Tuite et 202 
al. 2015).  Cox identified (correctly) what he referred to as a ‘self-replicating particle’ in 203 
the cytoplasm that was involved in the inheritance of the trait.  In yeast, there were three 204 
known principle cytoplasmic components that were inherited:  mitochondrial DNA, yeast 205 
killer dsRNA plasmids, and 2-micron circle plasmids.  The [PSI+] trait was none of these, 206 
although its identity would remain a mystery for almost 30 years. 207 
Another strangely inherited trait in yeast was identified by Francois Lacroute in 1971 208 
(Lacroute 1971).  In this case the gene involved was called URE2 and the trait [URE3].  209 
Lacroute hypothesized that the trait was mitochondrially inherited, although several 210 
features would have been very unusual for a mitochondrial trait.  Lacroute also proposed 211 
an alternative to that idea, proposing that [URE3] was a ‘non-mitochondrial cytoplasmic 212 
replicon’ of unknown nature (Lacroute 1971).  Akin to [PSI+], the biochemical and 213 
genetic basis of [URE3] was not understood until the prion hypothesis had been in 214 
formulated.  Connection of these traits to the prion hypothesis (discussed next) will be 215 
described in section 3.7 below. 216 
 217 
2.6 The prion hypothesis 218 
In the animal TSEs, the hypothesis of a slow virus etiology was widely accepted, but data 219 
began to accumulate that put that etiology into question.  CJD in humans was clearly 220 
hereditary.  The scrapie agent was not inactivated by formalin or by UV radiation, which 221 
both inactivated known viruses (Alper et al. 1967; Pattison & Jones 1967).  Decades of 222 
struggle to find any nucleic acid in the scrapie agent continued to prove fruitless and 223 
several investigators suspected a purely proteinaceous infective nature for scrapie 224 
(Griffith 1967; Hunter et al. 1969; Prusiner, Hadlow, Garfin, et al. 1978; Prusiner, 225 
Hadlow, Eklund, et al. 1978; Prusiner, Groth, Cochran, McKinley, et al. 1980; Prusiner, 226 
Groth, Cochran, Masiarz, et al. 1980; Hadlow et al. 1980; Prusiner et al. 1981; Cho 1980; 227 
Merz et al. 1983). 228 
Despite the lack of evidence for nucleic acid playing a role in transmission for the TSEs, 229 
the scientists working in the field still had a healthy regard for the Central Dogma and 230 
were not ready to assume a protein-only inheritance for these diseases.  However, one 231 
scientist, Stanley Prusiner, was willing to push ahead with a formal hypothesis of a fully 232 
protein infective agent, something he called the ‘proteinaceous infectious particle’ or 233 
‘prion’ (Prusiner 1982).  This bold hypothesis, for which Prusiner would be awarded the 234 
Nobel Prize in Physiology or Medicine in 1997, was not proven overnight, and many 235 
lines of evidence were required to convince a skeptical scientific community.  This 236 
hypothesis would later be more widely applied to the inheritance of the unusual non-237 
Mendelian characters in yeast and what was learned in the study of prion diseases would 238 
prove applicable to the more general problem of human protein-misfolding diseases that 239 
were of a non-infectious nature as well. 240 
 241 
3. Evidence Found:  Identification of Animal, Yeast, and 242 
Other Prions 243 
3.1 Scrapie in sheep and goats 244 
TSEs have been found in a number of mammals, including humans (Table 2) with the 245 
longest studied being scrapie.  Sheep and goats affected with the neurological pathology 246 
of scrapie had been the subject of scientific investigation for centuries, with the first 247 
verified report published in Germany in 1750 (Leopoldt 1750) although cases were cited 248 
in other reports going back to 1732 in Spain and in England.  Leopoldt’s initial report 249 
postulates an infectious cause for scrapie although other scientists would debate whether 250 
hereditary or other causes were more likely for many years to come (reviewed in 251 
Schneider et al. 2008).  Experiments to prove transmissibility were undertaken many 252 
times, but had various deficiencies leading to continued disagreement.  Finally, beginning 253 
in 1936, Cuille and Chelle proved transmissibility by inoculating healthy animals with 254 
material from the central nervous systems of sick animals (Cuille & Chelle 1936; Cuille 255 
& Chelle 1938a; Cuille & Chelle 1938b; Cuille & Chelle 1938c; Cuille & Chelle 1939).   256 
Small wild sheep called mouflons are also susceptible to scrapie (J. Wood et al. 1992), as 257 
are goats (Cuille & Chelle 1939; J. N. Wood et al. 1992).   258 
Cuille and Chelle proposed a viral etiology for scrapie in their 1930s research, although 259 
other causes were still postulated by others.  A particular designation as a ‘slow virus’ 260 
disease (Sigurðsson 1954) became the common way to group this disease with CJD and 261 
Kuru as they were discovered.  As mentioned above, a protein-only transmission was also 262 
proposed by Griffith but did not immediately attract the support of the scrapie research 263 
community (Griffith 1967).  One difficulty in conducting this research was the long 264 
incubation in sheep, which was overcome by conducting experiments in mice (Chandler 265 
1961).  Although mice remained a workhorse in studying scrapie for decades, a later 266 
hamster model was also developed which dropped the incubation period from years in 267 
sheep to 150 days in mice to 60 days in hamsters (Kimberlin & Walker 1977). 268 
The prion protein was identified and called PrP, with the gene being called Prnp in sheep 269 
and goats.  Two forms were described:  PrPSc (scrapie form) and PrPC (cellular normal 270 
form).  Many strains of scrapie were identified, mutations in the genes were identified, 271 
and it was found that some strains/mutations delayed onset of disease and others 272 
shortened the time to disease progression. 273 
Scrapie modes of transmission have been debated for many years.  Although 274 
experimental transmission can take several forms, the natural transmission of scrapie 275 
horizontally between individuals occurs through direct contact between animals and 276 
through contact with environmental contamination (reviewed in Schneider et al. 2008).  277 
Scrapie is predominantly acquired through the oral route and the placenta and amniotic 278 
fluid are the most common sources of oral infection, although fetal parts, feces, and milk 279 
have all shown infectivity (see Schneider et al. 2008). 280 
 281 
3.2 Bovine spongiform encephalopathy 282 
With the substantial neuropathological understanding of scrapie going back decades, 283 
veterinarians and scientists in the United Kingdom quickly noticed the arrival of a new, 284 
related disease.  Bovine spongiform encephalopathy (BSE) in cattle was identified in 285 
1987 (Wells et al. 1987).  BSE was noted for the classic neurological symptoms typical 286 
of spongiform encephalopathies:  ataxia (contributing to ‘downer cattle’ that cannot stand 287 
well), behavioral changes, anorexia, and death.  The practice of using rendered meat and 288 
bone meal (MBM) product (which contains nervous tissue) from sheep and cattle to 289 
increase protein in animal feed was immediately suspected as a potential epidemiological 290 
cause of the BSE outbreak (Taylor 1989; Matthews 1990) and UK and other government 291 
inquiries agreed with that stance, leading to changes in feeding practices across the globe.  292 
It is still debated whether BSE may have arisen from sporadic BSE entering the MBM 293 
food chain or whether it may have been scrapie in slaughtered sheep in the MBM (with a 294 
subsequent rare evasion of the species barrier) that led to the widespread BSE outbreak in 295 
the United Kingdom.  It was quickly recognized, however, that since a scrapie origin to 296 
the BSE outbreak was plausible, the possibility that BSE might also cross the species 297 
barrier into humans was equally plausible (Taylor 1989; Matthews 1990).  This 298 
prediction proved prescient, with the discovery of an unusual cluster of younger 299 
Creutzfeldt-Jakob patients (“variant” CJD) in the United Kingdom only a few years later 300 
in 1996 (see the next section for a fuller description).    301 
 302 
3.3 Kuru, CJD, other prion diseases in humans 303 
The first description of a human TSE disease (Table 2, bottom) was Creutzfeldt-Jakob 304 
disease in 1920-21 (Creutzfeldt 1920; Jakob 1921).  This rare, neurodegenerative disease 305 
(CJD) was characterized in people by loss of memory and judgment and increasing 306 
dementia, concomitant with loss of muscular coordination, significant personality 307 
changes, and impaired vision.  The proximate cause of these neurological deficits was 308 
death of neurons (as seen in MRI, Fig. 1A) and holes in brain tissue with concomitant 309 
buildup of plaques (as shown in histologic section, Fig. 1B).  CJD was found to occur in 310 
families but most cases were not associated with heredity and were termed sporadic CJD 311 
(sCJD).  sCJD is the most common human prion disease with ~85% of all cases, with the 312 
balance made up of familial CJD and other diseases (Prusiner 1989). 313 
Kuru (Gajdusek & Zigas 1959; Klatzo et al. 1959) bore many of the same neurological 314 
features as CJD and scrapie when it was identified among the Fore people of the Eastern 315 
Highlands of Papua New Guinea.  Originating from a Fore word meaning “to shake,” 316 
kuru was also known among the Fore as the ‘laughing sickness.’  The Fore engaged in a 317 
practice of mortuary or funerary cannibalism wherein the internal organs, including the 318 
brain, of the dead would be consumed by living relatives for spiritual purposes (Alpers 319 
1968).   When Australian colonial administrators and Christian missionaries suppressed 320 
the practice of cannibalism, the epidemic levels of kuru observed in the 1950s rapidly 321 
declined, although because of the long and variable incubation period seen in many TSEs 322 
the last sufferer of kuru is reported to have died in 2005 (Alpers 2008; Lindenbaum 2008; 323 
Anon 2009). 324 
Beginning in the 1990s, it was recognized that human disease caused by prions went 325 
beyond the sporadic or familial forms of CJD and the exotic and largely extinct kuru.  326 
Variant CJD (vCJD) was noted in the United Kingdom in 1996, with features consistent 327 
with a CJD diagnosis, but an earlier average age of onset (Will et al. 1996).  It was 328 
rapidly shown that the cause of the vCJD outbreak was consumption of food products 329 
from cattle infected with the BSE agent (Bruce et al. 1997).   330 
Iatrogenic CJD (iCJD) has been recognized since the 1980s.  In this form of CJD, 331 
improperly disinfected medical equipment, especially instruments used in brain surgeries, 332 
and also improperly prepared medicines, e.g., human growth hormone, have resulted in 333 
cases of CJD (Rappaport 1987; Marzewski et al. 1988; Mocsny 1991). 334 
Finally, a few other distinctive human diseases with a prion basis are recognized.  Fatal 335 
insomnia is a disease characterized by thalamic degeneration, progressive loss of 336 
neurological characteristics required for sleep, motor abnormalities, and hyperactivation 337 
of the autonomic nervous system (Lugaresi et al. 1986).  First identified was a familial 338 
form of this disorder referred to as fatal familial insomnia (FFI) (Lugaresi et al. 1986) 339 
although later work found evidence of sporadic cases (sFI) as well (Montagna et al. 2003; 340 
Barash 2009; Moody et al. 2011).   Gerstmann–Sträussler–Scheinker (GSS) syndrome 341 
(reviewed in Liberski 2012) is a very rare hereditary disease inherited in autosomal 342 
dominant fashion originally noted over 100 years ago in Austria (Dimitz 1913) and more 343 
fully described in the 1920s and 1930s (Gerstmann 1928; Gerstmann et al. 1936).  GSS 344 
features dysarthria, ataxia, and progressive dementia, and its causative mutations in the 345 
human PRNP gene were identified in 1989 (Hsiao et al. 1989).  The disease effects were 346 
experimentally recreated in mice shortly thereafter (Hsiao et al. 1990).  Other variations 347 
in PRNP associated with disease in human families have been reported in unrelated 348 
groups around the world (e.g., Hsiao et al. 1991; Dlouhy et al. 1992). 349 
 350 
3.4 Prion diseases in other mammals 351 
Other mammalian prion diseases have been described (Table 2, top) (reviewed in 352 
Greenlee & Greenlee 2015).  An infectious encephalopathy affecting ranched mink 353 
appeared as early as 1947 in the United States with a formal description in 1965 354 
(Hartsough & Burger 1965; Burger & Hartsough 1965; Marsh & Hanson 1969; Barlow 355 
1972).  A disease of abnormal behavior, severe anorexia, and rapid death was observed 356 
1967-1979 in cervids (elk and deer) in Colorado and Wyoming (Williams & Young 357 
1980).  Because of the substantial wasting caused by the anorexia in these animals, it was 358 
named Chronic Wasting Disease (CWD).  Despite its different name, it was immediately 359 
recognized, based on distinctive histopathology, as a spongiform encephalopathy in the 360 
same line as scrapie.  Feline spongiform encephalopathy (FSE) was identified in 361 
domestic cats (Wyatt et al. 1991; Pearson et al. 1991; Pearson et al. 1992) and later in 362 
many wild cats including lions, puma, ocelot, and cheetah (e.g., Eiden et al. 2010).  An 363 
abstract from the Prion 2012 meeting in Amsterdam reported the case of a 9 week old 364 
Rottweiler with canine spongiform encephalopathy (David & Tayebi 2012).  However, 365 
no further reports on canine spongiform encephalopathy have been published.  Even 366 
though the list of species with documented cases (Table 2) is small, it remains likely that 367 
yet-undiscovered spongiform encephalopathies exist in all mammals. 368 
 369 
3.5 Prions in other eukaryotes 370 
Prion-based TSEs have only been reported in mammals.  However, homologues of the 371 
PrP-encoding gene have been identified in birds, reptiles, amphibians, and fish (reviewed 372 
in Schätzl 2007 and Málaga-Trillo et al. 2011).  It is unknown whether the variant PrP 373 
sequences in these species (which have several divergent features depending on 374 
taxonomic grouping) can form bona fide prions, amyloids, or whether TSE-like disease is 375 
present in these animals.   376 
A protein with prion characteristics, when expressed in the yeast system, was also 377 
recently found in Arabidopsis, making it the first potential plant prion-like protein 378 
(Chakrabortee et al. 2016; discussed in Chernoff 2016). 379 
 380 
3.6 Evidence in support of the prion hypothesis in mammalian disease 381 
The proposal of a fully proteinaceous infectious agent and the coining of the term prion 382 
for that agent (Prusiner 1982) did not coincide with irrefutable proof of the prion 383 
hypothesis, and certainly did not immediately satisfy all criticisms with the hypothesis.  384 
Instead, the formal statement of the prion hypothesis as the causative agent of scrapie 385 
built upon the steady framework of evidence from earlier studies (Griffith 1967; Hunter 386 
et al. 1969; Prusiner, Hadlow, Garfin, et al. 1978; Prusiner, Hadlow, Eklund, et al. 1978; 387 
Prusiner, Groth, Cochran, McKinley, et al. 1980; Prusiner, Groth, Cochran, Masiarz, et 388 
al. 1980; Hadlow et al. 1980; Prusiner et al. 1981; Cho 1980; Merz et al. 1983) and 389 
provided a scaffold upon which to place further empirical data to support or refute it.  390 
Some of the major lines of support are provided here, although other texts provide a more 391 
complete picture of the supporting arguments (Hörnlimann & Riesner 2007; Colby & 392 
Prusiner 2011b; Zabel & Reid 2015) 393 
The laboratories of Charles Weissmann, Stanley Prusiner, and Leroy Hood, together 394 
published the identification of the gene responsible for scrapie, which encoded a protein 395 
in sheep for which several normal functions have since been determined, but no single 396 
well-determined role has been pinpointed.  The gene, Prnp in animals and PRNP in 397 
humans, encoded the PrP (prion) protein (Oesch et al. 1985).  The Prnp gene in mice was 398 
found to be co-located with a previously identified marker of mouse scrapie called Sinc 399 
(Dickinson et al. 1968), which provided evidence that a normal cellular (non-viral) gene 400 
locus was associated with the disease protein (Carlson et al. 1986; Hunter et al. 1987; 401 
Carlson et al. 1988).  Mice that were devoid of the PrP gene proved to be resistant to 402 
scrapie (Büeler et al. 1993).  Mice that were modified to express their Prnp gene with the 403 
mutation corresponding to human FFI were spontaneously stricken with prion disease 404 
(Jackson et al. 2009).  Prions can be made in bacteria and cause disease in mice 405 
(Legname et al. 2004).  Reconstitution of the prion using a cyclic amplification technique 406 
was possible with both partially purified substrates (Deleault et al. 2005) and with 407 
infectious particles created in vitro (Barria et al. 2009).  Further studies building on this 408 
theme show that it is possible to make recombinant infectious particles de novo in 409 
bacteria and without amplification in a clean laboratory that has never seen prions (Zhang 410 
et al. 2013).   411 
The prion hypothesis holds that a natively folded cellular protein can assume an 412 
abnormal, infectious and pathological shape that can be propagated between cells and 413 
between organisms without the need for any nucleic acid or viral structures.  Although 414 
some scientists remain doubtful (Manuelidis 2007; Bastian et al. 2007; Manuelidis et al. 415 
2009; Somerville & Gentles 2011; Manuelidis 2013), with the evidence above and other 416 
lines of evidence, most scientists are now convinced of the validity of the prion 417 
hypothesis in mammals (and, as seen below, in yeast). 418 
 419 
3.7 Reed Wickner’s keen observations in yeast 420 
The yeast traits (discussed in section 2.5 above) that resulted from Cox and Lacroute’s 421 
mysterious non-mitochondrial cytoplasmic particles in the baker’s yeast Saccharomyces 422 
cerevisiae (Cox 1965; Lacroute 1971) had long been on the mind of Reed Wickner, yeast 423 
geneticist and virologist.  He began studies in 1989 (Wickner 2012) to see if Prusiner’s 424 
proposed framework of protein-only inheritance (Prusiner 1982) could be applied to the 425 
[URE3] trait. 426 
In 1994, Reed Wickner published this work of careful and keen observation, showing that 427 
[URE3] trait resulted from a heritable conformation of the Ure2 protein, wherein it took 428 
on a prion form that was passed to daughter cells (Wickner 1994).  This elegant 429 
hypothesis accounted for all of the unusual features of the non-Mendelian cytoplasmic 430 
inheritance of [URE3] that had vexed scientists for 30 years and immediately also 431 
suggested a mechanism for the inheritance of [PSI+] as well (Wickner 1994; reviewed in 432 
Tuite et al. 2015).  [PSI+] proved to be a heritable prion state of the Sup35 protein in 433 
yeast (Doel et al. 1994; Ter-Avanesyan et al. 1994; Patino et al. 1996; Paushkin et al. 434 
1996). 435 
In establishing the prion hypothesis for yeast proteins, Wickner had laid out three genetic 436 
criteria for a prion that should readily distinguish them from agents containing nucleic 437 
acid, such as viruses (Wickner 1994; Wickner 2012):  (a) the infection should be curable 438 
but reversible, (b) the overproduction of the relevant cellular gene should increase the 439 
frequency of prion formation, and (c) the prion-positive phenotype, inactivating a cellular 440 
protein’s normal function, should match that of the loss-of-function mutant form of the 441 
same protein.  All three of these criteria are met in [URE3] and [PSI+], where, first, low 442 
concentrations of guanidine HCl can cure prions (Tuite et al. 1981; Lund & Cox 1981; 443 
Ferreira et al. 2001), but prions can then arise de novo in cured strains because the normal 444 
protein is still present.  (Viruses would need to have nucleic acid reintroduced from 445 
outside the cell.)  Secondly, overproduction of prion proteins increases the concentration 446 
of these proteins in the cell resulting in more prion formation (Chernoff et al. 1993; 447 
Wickner 1994; Derkatch et al. 1996), presumably due to an increase in the probability of 448 
the misfolding event that initiates prion or oligomer formation. Finally, the URE2 and 449 
SUP35 genes, respectively, are necessary for the formation of the [URE3] and [PSI+] 450 
prions, and the prion phenotype is the same as that of loss-of-function mutations for each 451 
gene (Aigle & Lacroute 1975; Cox et al. 1988; Wickner 1994). 452 
With these criteria satisfied, further characterization of the nature of these prion proteins 453 
could begin.  Through the work of Wickner’s laboratory and the labs of Michael Ter-454 
Avanesyan, Susan Lindquist, and Susan Liebman, and others, [URE3] and [PSI+] began 455 
to reveal their secrets.  Comparisons with the structures of animal prions would show 456 
many commonalities. 457 
 458 
3.8 Other fungal and invertebrate prions 459 
Although they are not further discussed in this review, prions in other fungi and 460 
invertebrates have also been identified, which differ in some way from the known yeast 461 
and animal prions.  For example, there is another fungal prion that differs somewhat in 462 
structure from the well-characterized yeast prions:  [Het-s] the prion form of the HET-s 463 
protein in Podospora anserina (Coustou et al. 1997; Baxa et al. 2007; Mathur et al. 2011; 464 
Wan & Stubbs 2014; Wickner et al. 2016).  Enzymatic and non-amyloid prions have also 465 
been identified, e.g., the yeast protease B (Jones 1991; Roberts & Wickner 2003) and the 466 
poly-A binding protein CPEB in Aplysia californica (Si, Lindquist, et al. 2003; Si, 467 
Giustetto, et al. 2003; Si et al. 2010; Stephan et al. 2015; Si & Kandel 2016).   468 
 469 
4. What Makes a Prion:  Features that Define Prions 470 
4.1 Defining features of prions 471 
In the course of finding evidence for the prion hypothesis in animals and fungi (see 472 
section 3 above), many other characteristics about their biochemical and biophysical 473 
nature were also noted.   474 
The primary physical characteristic of prions found in prion diseases is that these diseases 475 
exhibit amyloid deposits in nervous tissue (detailed below).  In the course of early studies 476 
of these diseases, the amyloid deposits were found to be stainable with agents such as 477 
Congo red.  After the identity of amyloid as protein rather than either carbohydrate or 478 
lipid, amyloid proteins were also found to be insoluble, protease and detergent resistant, 479 
beta-sheet rich, and prone to assemble into aggregate and fibril structures.  480 
In this section, I detail the work that uncovered the overall amyloid structures of the 481 
animal (section 4.2) and yeast (section 4.3) prions.  Knowledge of the essential structural 482 
and functional nature of prions (PrP and the yeast prions, chiefly) has logically led to the 483 
search for other prions in mammals and in yeasts (section 4.4), although the success rate 484 
for finding new prions has been much greater in yeast.  Other characteristics that define 485 
prions have also been noted over years of study (section 4.5) and these characteristics are 486 
leading to insight into prion, amyloid, and similar diseases and their pathophysiologies. 487 
 488 
4.2 Structural features of animal prions 489 
Animal prions are characterized by certain structural and biochemical features.  The well-490 
characterized mammalian PrP prion is known to form amyloid fibrils.  Amyloids 491 
(misidentified by Rudolf Vircow in 1854 as related to starch—amylum—because amyloid 492 
is stained by iodine like starch) were found in nervous tissue and associated with all of 493 
the prion diseases above as well as with other amyloidoses including Alzheimer’s disease 494 
(Sipe & Cohen 2000).  Amyloids were found to be different from starch under light 495 
microscopy on the basis of a green/yellow/orange birefringence when stained with Congo 496 
red dye and illuminated under polarized light (Howie 2015).  In 1959 the first electron 497 
micrographs of amyloids showed fibrils of 80-100 Å in width and of variable length (Sipe 498 
& Cohen 2000).   Amyloids were resistant to protease treatment (McKinley et al. 1983; 499 
Oesch et al. 1985; Manuelidis et al. 1985; Kitamoto et al. 1986) and detergent treatment 500 
(Glenner et al. 1969; Prusiner et al. 1987). 501 
Native PrP protein has been crystallized (Antonyuk et al. 2009) and solved by NMR 502 
(Riek et al. 1996; James et al. 1997; Riek et al. 1998; Zahn et al. 2000), but working with 503 
non-native and insoluble amyloid forms of proteins is problematic for traditional 504 
structural techniques.   The secondary conformations found in amyloids were first 505 
elucidated in the 1960s and showed a beta-sheet rich structure with the beta-sheet axes 506 
perpendicular to the long axis of each fibril (the so-called cross-beta structure) (Eanes & 507 
Glenner 1968).  Many subsequent studies have borne out the basic conclusion for 508 
different animal amyloid and prion proteins (Harper et al. 1997; Sunde et al. 1997; 509 
Lyubchenko et al. 2012; Tycko & Wickner 2013; Groveman et al. 2014) with the latter 510 
papers clarifying a parallel in-register intermolecular beta-sheet structure for the amyloid 511 
forms of these proteins.  512 
Amyloid proteins self-assemble into large, complex aggregates and fibrils on the basis of 513 
their unusual beta-sheet rich tertiary conformations (Fig. 2).  The process of fibril 514 
formation has a number of steps (Dobson 2003; Gregersen et al. 2005; Chiti & Dobson 515 
2006; Tanaka et al. 2006; Maji et al. 2009; Naeem & Fazili 2011; Eisenberg & Jucker 516 
2012; Knowles et al. 2014).  One model is presented here, although other models have 517 
been proposed (Colby & Prusiner 2011b).  In this model, conversion of native to amyloid 518 
form is a rare event (Fig. 2A) where the misfolded proteins can associate and cause 519 
conformational conversion of other natively-folded proteins (Fig. 2B).  Through this 520 
process, oligomers are formed (Fig. 2C) that eventually assemble into longer fibrils (Fig. 521 
2D).  Chaperone proteins and other proteins may be involved in cleaving long fibrils into 522 
smaller pieces (Fig. 2D to Fig. 2C).  It has been noted that the amyloid oligomer stage 523 
(Fig. 2C) is likely the most toxic to cells and tissues (reviewed in Kayed & Lasagna-524 
Reeves 2013 and Verma et al. 2015).  It is also worth noting that while amyloid 525 
formation is clearly a process that involves cytotoxicity and histotoxicity, production of 526 
rod-type and other non-amyloid aggregates is also possible with PrP and disease can still 527 
result (Wille et al. 2000). 528 
The Prnp/PRNP genes in animals and humans encode the PrP protein (Oesch et al. 1985; 529 
Basler et al. 1986) and the domain structure of the translated PrP protein (Fig. 3A) has 530 
been long studied and dissected for interesting and notable features (reviewed in Colby & 531 
Prusiner 2011).  The mammalian prion protein, PrP, as shown in Fig. 3A, contains five 532 
octarepeats (consensus sequence: PHGGGWGQ) (Brown et al. 1997).  The similar length 533 
of each repeat and number of repeats found in each protein is suggestive of some 534 
important function.  The importance of the repeats in PrP is underscored because PrP 535 
repeat expansion is associated with dominant inherited prion disease (Wadsworth et al. 536 
2003; Prusiner et al. 1998) and removal of the repeats in a mouse model of disease slows 537 
progression (Flechsig et al. 2000).  The profile of the repeat structures in PrP rose further 538 
when it was noted that there are compositional similarities between the repeats in PrP and 539 
in the yeast prion Sup35 (Fig. 3B, with similar prevalence to PrP of the amino acids 540 
proline, glycine, and glutamine in the repeats, for example, as detailed in the next 541 
section).  Indeed, in the context of yeast Sup35, its oligopeptide repeat domain (ORD) 542 
repeats can even be functionally replaced with PrP repeats and propagation is unimpaired 543 
(Parham et al. 2001).  And in a result analogous to the in vivo repeat expansion 544 
experiment, Sup35 aggregates with increasing numbers of PrP repeats have reduced times 545 
to fiber formation in vitro (Kalastavadi & True 2008).  Given the similarity between 546 
Sup35 and PrP repeats and the presence of repeat elements in other yeast prion 547 
domains—Rnq1 and New1 (Osherovich et al. 2004; Vitrenko et al. 2007)—primary 548 
sequence effects could be an important consideration for propagation of prions.  549 
However, as discovered in yeast prions (section 4.3 below), primary sequence elements 550 
like repeats may instead represent a convenient genetic method of rapidly expanding 551 
amino acid compositional biases that lead to prion formation. 552 
Other structural features have been noted for PrP as well (Fig. 3A).  It is doubly-553 
glycosylated near the cysteines involved in a disulfide bridge and has a GPI-anchor for 554 
cell membrane attachment.  Unlike the repeat structures noted above, these features have 555 
not been generally noted in the yeast prions and so may represent less commonly found 556 
domains or characteristics of prion proteins.  557 
 558 
4.3 Structural characterization of yeast prions 559 
Although the non-Mendelian cytoplasmic characters [URE3] and [PSI+] from yeast were 560 
shown to be prions in 1994, many aspects of their fundamental biology remained to be 561 
worked out.  Though Wickner had shown a protein-only inheritance in the yeast prions 562 
consistent with that previously proposed in mammalian PrP, whether the yeast prions 563 
would share the basic protein structure of an abnormal amyloid fold was not known.  The 564 
amyloid structure would first be noted for [PSI+] (King et al. 1997) and [URE3] (Taylor 565 
et al. 1999) and the predicted (Ross, Minton, et al. 2005) parallel in-register beta-sheet 566 
structure observed for PrP would be noted for [URE3] (Baxa et al. 2007), [PSI+] 567 
(Wickner et al. 2008; Shewmaker et al. 2009; Chen et al. 2009) and others (Chen et al. 568 
2009; Engel et al. 2011).  Yeast prions, found to generally form amyloid structures, were 569 
also protease and detergent resistant (Masison & Wickner 1995).   570 
The full history of yeast prion characterization is outside of the scope of this review (for a 571 
fuller discussion see Wickner 2012), but I will discuss several key structural and 572 
biochemical features of yeast prions beyond amyloid structure in this section. 573 
Shortly after Wickner’s 1994 paper, it was rapidly noted by Yury Chernoff in Susan 574 
Liebman’s lab in collaboration with Susan Lindquist’s lab, that the chaperone protein 575 
Hsp104 was involved in propagating the [PSI+] prion to daughter cells and cells that mate 576 
with [PSI+] cells (Chernoff et al. 1995; Lindquist et al. 1995) and this process would be 577 
mediated by Hsp104’s ability to cleave fibrils into smaller pieces (reviewed in Sweeny & 578 
Shorter 2016, see also the arrow from Fig. 2D to 2C).  579 
The function of yeast prions is a matter of some debate.  Unlike the TSEs which greatly 580 
hamper neurologic function and are uniformly fatal when symptoms begin, prions in 581 
yeast, due to short generation time and rapid growth, could be beneficial (True & 582 
Lindquist 2000; Suzuki & Tanaka 2013) or harmful (Nakayashiki et al. 2005; 583 
McGlinchey et al. 2011; Wickner et al. 2011).  In fact, there is no reason to expect that 584 
prions could not be both sometimes beneficial and sometimes harmful to the cell. 585 
The normal function of each host protein, Sup35 and Ure2, were exploited as assays for 586 
the detection of prion activity as well.  Detection of [URE3] relies on growth 587 
characteristic of the cells in the presence of a good nitrogen source.  [URE3] cells in this 588 
circumstance would be able to take up ureidosuccinate, an intermediate compound in 589 
uracil biosynthesis, while cells without the [URE3] prion cannot uptake ureidosuccinate 590 
(Lacroute 1971). This ability has been used to assay for the presence of the [URE3] prion 591 
but it can be a difficult assay to work with (Brachmann et al. 2006).  Assaying for [PSI+] 592 
is a much easier-to-interpret test.  Because Sup35 is an ‘omnipotent suppressor’ that can 593 
read-through stop codons (Ter-Avanesyan et al. 1994), in a cellular background 594 
containing an ade2-1 (or similar) mutant with a premature stop codon, suppression by the 595 
eRF3 function of Sup35 will lead to read-through in prion-containing cells and no read-596 
through in prion-negative cells (Fig. 4A).  Because the ade2 mutant is non-functional 597 
without read-through, oxidized P-ribosylaminoimidazole in the adenine biosynthetic 598 
pathway will accumulate and the cells will be red in color when plated on limiting 599 
adenine (Fig. 4B, right).  If the prion state removes active Sup35 from the cell by 600 
sequestering it in fibrils, read-through will occur and the cell will remain wild-type in 601 
color (Fig. 4B, left).   602 
Unusually, both [URE3] and [PSI+] were found in genetic screens where, uncommonly, 603 
a loss of function event for either protein was advantageous to the cell (Lacroute 1971; 604 
Cox 1965).  In most cases, detecting such a rare loss of function event would be 605 
extremely difficult.  However, structural studies of [URE3] and [PSI+] revealed an 606 
exploitable feature of these proteins that could help identify other, similar, prions.   607 
Sup35, the protein that forms the [PSI+] prion, features three domains (Fig. 3B): an N-608 
terminal (N) domain that is responsible for prion formation (also called a prion forming 609 
domain—PFD—or prion-like domain—PrLD), a charged middle domain (M) and a C-610 
terminal catalytic domain (C) responsible for the nonsense-suppression (eRF3) function 611 
of Sup35 (Ter-Avanesyan et al. 1993).  The N domain is rich in glutamine and asparagine 612 
(Q/N) amino acid residues.  Within the N domain, the nucleation domain (ND), the first 613 
39 amino acids, is more Q/N-rich than the portion of the N domain immediately after 614 
(DePace et al. 1998).  This section, the oligopeptide repeat domain (ORD), is also 615 
enriched in glutamine and asparagine, but is primarily noted for having a series of 5 ½ 616 
imperfect repeats (Fig. 3B) (Osherovich et al. 2004; Shkundina et al. 2006).  Ure2 also 617 
has a substantial Q/N-tract that is required for prion formation (Masison & Wickner 618 
1995).  What made these Q/N-rich domains of even greater interest was that these 619 
domains were modular (the compact Q/N-rich portion of the protein enabled the protein 620 
to assume an amyloid shape without contribution from the rest of the three-dimensional 621 
structure) and also transferrable (that amyloid/prion forming ability could be fused to 622 
many other proteins and cause them to also become amyloid/prion forming) (Li & 623 
Lindquist 2000; Baxa et al. 2002).  In both the Sup35 and Ure2 yeast prion proteins, the 624 
prion domain was also dispensable, and could be deleted without affecting catalytic 625 
functions (domains reviewed in Ross et al. 2005).   626 
The prion domains of the [URE3] and [PSI+] prions have a curious conformational 627 
property as well.  For almost all known proteins, three-dimensional structure and function 628 
are inextricably linked to the primary sequence, the ordered series of amino acids.  In the 629 
beta-sheet rich [URE3] and [PSI+] prions, it is possible to actually scramble the order of 630 
the amino acids in each PFD (using a random number generator) and retain both the 631 
amyloid structure and the prion function/effects in the cell (Ross, Edskes, et al. 2005; 632 
Ross et al. 2004; Ross, Minton, et al. 2005; Shewmaker et al. 2006).   633 
The ability to scramble amino acid order while retaining structure and function is an 634 
especially curious property given that, as detailed in section 4.2, Sup35 has been utilized 635 
as a model for examining the role of prion protein repeats in formation and propagation 636 
of aggregates (Parham et al. 2001; Dong et al. 2007; Tank et al. 2007; Kalastavadi & 637 
True 2008) and the mammalian PrP repeats have been repeatedly suggested to be 638 
important for disease (Wadsworth et al. 2003; Prusiner et al. 1998; Flechsig et al. 2000).   639 
In the case of [PSI+], the two portions of the PFD (the N-terminal ND region and the C-640 
terminal ORD region) have distinct amino acid compositions (Toombs et al. 2011).  The 641 
distinct compositions seem to relate to different functions of each subdomain:  the ND is 642 
required for nucleation or formation of the prion and the ORD is required to propagate or 643 
maintain the prion (DePace et al. 1998; Osherovich et al. 2004; Shkundina et al. 2006).  644 
The ability to scramble prion primary sequence and still generate functional prions led to 645 
important experiments, discussed below, useful in understanding yeast prions and in 646 
identifying new candidate prions. 647 
 648 
4.4 Making predictions:  Using biochemical knowledge of known prions to 649 
identify other prions and understand the prion structure-function 650 
relationship 651 
Given the longer history of study of the animal prions, it might be expected that after 652 
Prusiner’s prion hypothesis (Prusiner 1982) gained traction, other animal prions would be 653 
rapidly discovered.  That has not been the case, although some (bottom part of Table 2), 654 
including the alpha-synucleinopathies, appear to form bona fide infectious prions.  655 
Alpha-synuclein, which has no sequence similarity to PrP, has recently been reported 656 
using mouse animal and cell culture models of human multiple system atrophy (MSA) as 657 
a prion (Watts et al. 2013; Woerman et al. 2015; Prusiner et al. 2015; reviewed in 658 
Supattapone 2015).  Alpha-synucleinopathies aggregate alpha-synuclein with other 659 
proteins in pathological structures called Lewy bodies (Spillantini et al. 1997; Mezey et 660 
al. 1998) that are found in Parkinson’s disease, MSA, Lewy-body dementia, and some 661 
cases of Alzheimer’s disease (Yokota et al. 2002).  It is likely that other human prion or 662 
prion-like diseases may still await discovery.  True infectious prions in mammals have 663 
not been easily found, but as noted in section 5 below, the enlargement of the prion 664 
concept may instead show that other prion-like diseases have been hiding, perhaps, in 665 
plain sight. 666 
Despite difficulties in identifying new animal prions, a whole host of new candidate and 667 
verified yeast prions have been found since Wickner’s 1994 recognition of the prion 668 
hypothesis in Saccharomyces.  The ease of genetic screens and manipulation in yeast has 669 
made a host of different approaches possible.  These studies in turn have led to greater 670 
structural insights and each new observation has improved methods for identifying other 671 
prions, resulting in more discoveries.  The current list of likely yeast prions is ~18 in S. 672 
cerevisiae alone.  And because prions are a subset of aggregative proteins that form a 673 
major new class of human diseases and the proteins responsible for these human diseases 674 
share characteristics with yeast prions, identifying new prions in yeast (reviewed in 675 
MacLea & Ross 2011) is a topic of considerable interest with applications in human 676 
disease.   Several techniques have been used or proposed to identify new prions in yeast:  677 
(1) Prion-prion interactions; (2) Q/N-content or other composition; and (3) Other 678 
bioinformatics and proteomics methods.   679 
 680 
4.4.1 Prion-prion interactions help reveal new prions 681 
 682 
Prions interact frequently with other prions in yeast, and these interactions can have 683 
variable effects on prion formation and propagation (Gonzalez Nelson & Ross 2011).  684 
The [PIN+]/[RNQ+] prion has been most well-studied in its effects on other prions, 685 
particularly its ability to promote formation of the [PSI+] prion (Derkatch et al. 1997; 686 
Derkatch et al. 2000; Derkatch et al. 2001).  The identification of [PIN+]/[RNQ+], 687 
described below, allowed Irina Derkatch to perform a genetic screen to identify factors 688 
that could substitute for [PIN+] in allowing [PSI+] formation (Derkatch et al. 2001).  This 689 
method identified 11 candidate prions, of which one was shown to be prion-like in certain 690 
assays but has not been shown to form prions in its native state (New1), and two were 691 
identified as likely prions (Swi1 and Cyc8) (Derkatch et al. 2001; Du et al. 2008; Patel et 692 
al. 2009).  This genetic screen was unique to [PIN+] and given that little is known about 693 
the seeding or other mechanism responsible for the behavior of [PIN+] in the cell, this 694 
method has not been used in additional screens. 695 
 696 
4.4.2 Q/N or other amino acid composition as a tool for prion identification 697 
 698 
[PSI+], encoded by the SUP35 gene in yeast, has a prion-forming domain (PFD) that is 699 
both modular and transferable and has an extremely easy-to-use and robust assay for 700 
prion formation (Fig. 4 and see above), making it the ideal platform on which to test other 701 
candidate prions.  A classical experimental scheme using Sup35 in this manner involves 702 
replacing the N domain (PFD) of Sup35 (see Fig. 3B) with any candidate ORF and then 703 
assessing its function in the ade2-1 assay conventionally used to monitor [PSI+] function 704 
(Fig. 4).  Using this scheme, additional prions would soon be identified in yeast, 705 
including [NU+] encoded by New1 (Michelitsch & Weissman 2000) and [PIN+]/[RNQ+] 706 
encoded by Rnq1 (Santoso et al. 2000; Sondheimer & Lindquist 2000; Derkatch et al. 707 
2001).  The PFDs of New1 and Rnq1 were also Q/N-rich and also transferrable, 708 
conferring the ability to aggregate even on the green fluorescent protein (GFP) in the 709 
absence of Sup35 (Sondheimer & Lindquist 2000; Osherovich & Weissman 2001; 710 
Osherovich et al. 2004).  The New1 PFD has additional similarities to Sup35, including 711 
separation of the formation and propagation functions within the PFD (Osherovich et al. 712 
2004, discussed below for Sup35). 713 
When New1 and Rnq1 were identified and shown to have similar Q/N content and 714 
characteristics to Sup35 and Ure2, two large-scale bioinformatics screens looking for 715 
Q/N-rich predicted prions in the yeast proteome were undertaken, in Jonathan 716 
Weissman’s lab (Michelitsch & Weissman 2000) and by Paul Harrison and Mark 717 
Gerstein (2003).  Melissa Michelitsch found 107 candidate yeast prion proteins, including 718 
most (8/11) found by Irina Derkatch, all four of the previously identified prions (Ure2, 719 
Sup35, New1, Rnq1) and four that were later shown to be bona fide prions (Swi1, Cyc8, 720 
Mot3, Sfp1) (Michelitsch & Weissman 2000; Du et al. 2008; Patel et al. 2009; Alberti et 721 
al. 2009; Rogoza et al. 2010).  Paul Harrison found 172 prion candidates of which 722 
101/172 were found by Michelitsch and 9/11 of the proteins found by Irina Derkatch in 723 
her genetic screen (Harrison & Gerstein 2003).  All 8 of the proven/likely prions found 724 
above were also found in this study (Ure2, Sup35, Rnq1, Swi1, Cyc8, Mot3, Sfp1).  725 
Michelitsch and Harrison both identified a large number of candidate prion proteins, but 726 
determining which of these candidates to examine further was not obvious given the 727 
methods used.  A combination of the bioinformatics screen with an experimental 728 
approach was necessary. 729 
The method of fusing prospective candidate PFDs to Sup35 to test prionogenicity and 730 
three other aggregation assays were used in a major study out of Susan Lindquist’s lab to 731 
address this central criticism of previous bioinformatics screens.  In this study (Alberti et 732 
al. 2009), a computational tool called a hidden Markov model (HMM) was first used to 733 
identify the 100 most-similar proteins to Ure2, Sup35, Rnq1, and New1.  In a mammoth 734 
experiment, each of those 100 ORFs was then tested in four different tests of prion-like 735 
activity, and 23 proteins were found that could induce prion formation in the context of 736 
Sup35 (Alberti et al. 2009).   This method did not identify all potential prions since two 737 
known prion proteins, Cyc8 and Mot3, did not show prion activity in this assay.  Showing 738 
the utility of this combined bioinformatics/empirical approach, although 67/100 of the 739 
ORFs had been previously implicated by Michelitsch and Harrison (Michelitsch & 740 
Weissman 2000; Harrison & Gerstein 2003), most did not have prion activity in one, two, 741 
three, or four of the prion candidate testing methods (Alberti et al. 2009).   742 
The enormous combined screen of Simon Alberti and Randal Halfmann in Susan 743 
Lindquist’s lab (Alberti et al. 2009) provided a data set of immense value, adding in the 744 
experimental results for all four assays of aggregative/prion activity to the computational 745 
screens previously conducted.  Still, within the data set generated, there was found to be 746 
no substantial relationship between the degree of similarity of each of the 100 ORFs to 747 
previously known prion sequences with their results in the four assays (Alberti et al. 748 
2009; Toombs et al. 2010; Ross & Toombs 2010).  While at first blush this suggests that 749 
amino acid composition may not be the main determinant of prion propensity, the 750 
incompleteness of previous knowledge on what made a prion and the small sample size 751 
likely meant that the algorithm was not optimized for this situation.  What was needed 752 
was an experiment that would give scoring values for each amino acid so that an increase 753 
or decrease in propensity to form prions could be calculated, without relying on 754 
previously discovered yeast prions.       755 
In Eric Ross’s laboratory, Trey Toombs used a scrambled version of Sup35 and replaced 756 
two short segments with a random sequence to generate two libraries of mutants (Toombs 757 
et al. 2010; Ross & Toombs 2010). For each library, different regions of the Sup35 758 
protein nucleation domain were modified and he then compared (in each library) the 759 
amino acid composition for a naïve subset of clones (with no selection) with a subset that 760 
could form prions and generated a prion-propensity score for each amino acid.  This 761 
allowed regions and whole ORFs and proteomes to be scanned and scored to evaluate 762 
overall predicted prion propensities.  Using another algorithm, FoldIndex, that measures 763 
order/disorder propensity (Prilusky et al. 2005), Toombs found that known yeast PFDs 764 
had extended disordered regions with only modest prion propensities (Toombs et al. 765 
2010; Ross & Toombs 2010).  Although not a perfect predictor, this method did improve 766 
(Toombs et al. 2010) on the blind HMM method used in Lindquist’s lab and was 767 
reasonably effective at predicting prion propensities for the proteins examined in the four 768 
assays of aggregative/prion function (Alberti et al. 2009).  The resulting algorithm for 769 
screening yeast proteins for prion propensity was named PAPA (Toombs et al. 2010; 770 
Ross & Toombs 2010; Ross et al. 2013).   771 
The Toombs experiment measured, by its design, the combined processes of prion 772 
formation and prion propagation or maintenance.  A follow-up study showed that the two 773 
subdomains within the PFD of Sup35 had amino acid compositions that were not 774 
identical.  That is, the composition of the ND (nucleation domain responsible for 775 
formation) and the ORD (responsible for maintenance) of Sup35 were different, and 776 
therefore propagation of prions to daughter cells had slightly different compositional 777 
requirements than nucleation (Toombs et al. 2011).  Further work addressed this 778 
compositional bias and allowed calculation of separate prion maintenance propensities 779 
(MacLea et al. 2015), which may in the future allow these processes to be better dissected 780 
and lead to more accurate prediction algorithms for fully-functional prions. 781 
 782 
4.4.3 Other bioinformatics and proteomics methods for prion identification 783 
 784 
Numerous algorithms have been developed to predict protein aggregation propensity, 785 
chiefly using the mammalian amyloids as a basis.  Algorithms including TANGO 786 
(Fernandez-Escamilla et al. 2004), Zyggregator (Tartaglia et al. 2008), BETASCAN 787 
(Bryan et al. 2009), Waltz (Maurer-Stroh et al. 2010) and ZipperDB (Goldschmidt et al. 788 
2010) have been somewhat successful at finding known amyloids in mammalian 789 
databases, but have had less utility in identifying yeast prions.  Although there is 790 
probably more to the story, the amyloidogenesis in both systems is thought to be rather 791 
different.  Mammalian amyloids appear to require a shorter, highly amyloidogenic 792 
stretch, while yeast prions appear to require longer stretches of modest prion propensity 793 
with intrinsic disorder as estimated by FoldIndex (Esteras-Chopo et al. 2005; Prilusky et 794 
al. 2005; Ross & Toombs 2010).  Newer algorithms focused on yeast prions, such as 795 
ArchCandy, which incorporates three-dimensional modeling, may prove useful as well 796 
(Bondarev et al. 2013) but at the moment no verified new prions have been identified 797 
using these methods.   798 
Simulations of molecular dynamics for short peptide stretches found commonly in 799 
mammalian prions were used in the creation of some of the algorithms above and have 800 
shed some light on how the conformational conversion process from native to amyloid 801 
shape may occur at the molecular level.  Similar simulations for the Q/N-rich prions have 802 
also been undertaken (Halfmann et al. 2011; Berryman et al. 2011).  Proteomics methods 803 
including two-dimensional gels and mass spectrometry have been proposed and used in 804 
small studies, but the insolubility of the amyloidogenic proteins makes these kinds of 805 
techniques very tricky to interpret.  Other methods may prove useful in the future for 806 
identification of more amyloid and prion proteins.  Any such method developed will need 807 
to work around difficult intrinsic properties of these proteins, including insolubility, 808 
protease and detergent resistance, and more.  Methods that are not biased in the same 809 
ways as earlier studies (looking only at Q/N-rich proteins, relying on fusion to Sup35 for 810 
an assay, etc.) will likely yield the most fruit in years to come.  One such study that 811 
exploits the difficult intrinsic properties of prion and amyloid proteins was recently 812 
published (Kryndushkin et al. 2013) and may be a useful template for future proteomics 813 
experiments to identify new prions or similar proteins. 814 
 815 
4.5 Strains 816 
 817 
In the previous parts of section 4, overall physical structures of animal (4.2) and yeast 818 
(4.3) prions have been examined, showing key features of these proteins, e.g., amyloid 819 
structure, staining properties, protease and detergent resistance, domain structures, repeat 820 
sequences, and amino acid compositions.  These properties of ‘what makes a prion’ were 821 
the initial seeds upon which further studies have been built.  In learning to identify new 822 
prions, chiefly in yeast (4.4), new features of both yeast and animal prions and amyloids 823 
have been noted, further expanding the field’s knowledge of the essential characteristics 824 
and diversity of prions and amyloids.  One key, but unusual, feature of prions has not yet 825 
been discussed:  distinct prion strains. 826 
Like other pathogens, prions have strain differences and these strain differences are 827 
propagated when the prions are transmitted.  This was first noted in scrapie (Dickinson & 828 
Meikle 1969; Fraser & Dickinson 1973).  Animal prion strains appear to be caused by 829 
conformational diversity (different stable forms with tertiary conformational variability) 830 
being inherited more or less faithfully (Bessen & Marsh 1994; Telling et al. 1994; 831 
Collinge et al. 1996; Peretz et al. 2001; Colby & Prusiner 2011a).  Yeast prions have 832 
widely appreciated strain differences as well (King & Diaz-Avalos 2004; Tanaka et al. 833 
2004; Tanaka et al. 2006; Marcelino-Cruz et al. 2011; Huang et al. 2013) that appear to 834 
be passed vertically and can be passed ex vivo cell to cell using traditional experimental 835 
techniques as well.  Because prions are not easily passed horizontally in yeast it is unclear 836 
whether strains can be naturally transmitted this way.   837 
 838 
 839 
5. The Enlarging Prion Concept in Disease and Beyond  840 
5.1 Introduction 841 
 842 
Prion diseases such as the TSEs were ultimately identified and set apart from other 843 
diseases on the basis of their etiology by a ‘proteinaceous infectious particle’ or prion.  844 
While this was a useful designation in the early years of prion studies, when scientific 845 
consensus on the existence of prions was far from sure, it is now becoming clear that the 846 
segregation of prions from other agents of pathological protein aggregation is 847 
inappropriate.  For example, non-infective amyloids such as amyloid precursor protein 848 
(APP) and tau, when injected directly into the central nervous system of other animals, 849 
appear to be able to cause disease (Haass et al. 1995; Clavaguera et al. 2009).  Human 850 
patients have also acquired Lewy-body type pathologic inclusions from brain grafts 851 
(Kordower et al. 2008).  From these and other observations (e.g., Jucker & Walker 2011; 852 
Eisenberg & Jucker 2012), it appears clear that the line separating the infectious prions 853 
from the non-infectious amyloids or pathologic aggregates is thinner than previously 854 
thought.  As a result, the consensus is that the prion concept itself is enlarging to 855 
encompass other diseases of aberrant protein aggregation as well (Colby & Prusiner 856 
2011b; Walker & Jucker 2015).  857 
5.2 Developing a definition of a general category of prion-like conformational 858 
states 859 
 860 
It was recently proposed that a new category of prion and prion-like diseases should 861 
together share certain essential characteristics (Colby & Prusiner 2011b).  (1) A post-862 
translational conformational change occurs in a native protein to a form with high beta-863 
sheet content; (2) Oligomers are formed from the high beta-sheet protein forms and are 864 
toxic to cells; (3) Polymerization into fibrils results in reduced toxicity of the high beta-865 
sheet forms; (4) ‘Plaques,’ ‘tangles,’ or ‘bodies’ result from sequestration of the fibrils 866 
inside and outside of cells, in the central nervous system; and (5) Mutations in these 867 
proteins may cause familial heritability of these traits. 868 
5.3 Prion-like proteins, quasi-prions, and prionoids 869 
 870 
A growing awareness of the broad swath of prion-like phenomena has necessitated some 871 
new terms to distinguish these categories.  Paul Harrison’s lab has suggested the 872 
categories of prion and prion-like proteins, with the latter category made up of quasi-873 
prions and prionoids (Harbi & Harrison 2014).  Briefly, prions have firm evidence of 874 
prion behavior, with fully infective particles made in vitro (strongest evidence, e.g., 875 
Sup35) or not (weaker, e.g., Cyc8).  Quasi-prions behave similarly to prions but do not 876 
meet the infection requirements of a prion, but can still pass the quasi-prion to progeny 877 
(for example, the likely prionogenic proteins from the Alberti et al. 2009 study or RepA-878 
WH1 in bacteria).  Prionoids have been shown to propagate between cells in multicellular 879 
organisms (for example, Tau in Alzheimer’s disease).  Regardless of the specific 880 
nomenclature, the rising realization in the aggregation and prion communities that there 881 
is overlap and crosstalk between the fields that may allow leaps in one area to rapidly 882 
cross-pollinate to another area across these categories make an understanding of the 883 
relatedness of the concepts especially apt and timely.  For example, in the next section, 884 
the application of discoveries in the yeast realm to studies of familial human diseases 885 
illustrate that these prion-like phenomena clearly share a biochemical and cellular basis. 886 
 887 
5.4 The intersection of animals and yeast:  Studies of yeast prions have lead to 888 
understanding of human amyloid diseases 889 
Yeast prions have helped us to find amyloid proteins in humans.  Although PrP is by far 890 
the most well-studied human prion protein, Q/N-rich proteins are overrepresented in the 891 
human proteome (Michelitsch & Weissman 2000; Harrison & Gerstein 2003) and study 892 
of these proteins in the context of yeast has been useful for identifying aggregating 893 
proteins in humans (reviewed in Cascarina & Ross 2014).  All of the following suspect 894 
amyloid proteins were tested in the yeast prion model.  For example, amyloidogenic 895 
proteins generated from mutant TDP-43 alleles were linked with amyotrophic lateral 896 
sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer’s and Parkinson’s 897 
diseases (Neumann et al. 2006; Lagier-Tourenne et al. 2010; Johnson et al. 2009; Da 898 
Cruz & Cleveland 2011; Johnson et al. 2008).  Mutations in FUS/TLS, EWSR1, and 899 
hnRNPA1 and hnRNPA2B1 were shown to cause ALS in some families (Sun et al. 2011; 900 
Kwiatkowski et al. 2009; Vance et al. 2009; Daigle et al. 2013; Couthouis et al. 2012; 901 
Kim et al. 2013).  Additional human amyloid proteins have been found in this way as 902 
well (reviewed in Cascarina & Ross 2014), and it is extremely likely that additional 903 
discoveries will be made in the coming years by fusing advanced genetic and pedigree 904 
analysis of humans with the experimental virtues of the simple, well-worn yeast prion 905 
analysis system.  In undertaking studies such as these, it is interesting to note that these 906 
human proteins, in large part, share more sequence/structure characteristics with the yeast 907 
prions than they do with PrP, demonstrating that fundamental biology is at work, 908 
probably for all eukaryotic cells and perhaps for all cells. 909 
 910 
5.5 What ties together prion-like phenomena 911 
 912 
Abnormal accumulation of disease-specific protein aggregates is a hallmark of most 913 
neurodegenerative disorders.  These include Parkinson’s disease (PD), amyotrophic 914 
lateral sclerosis (ALS), multiple system atrophy (MSA), frontotemporal lobar 915 
degeneration (FTLD), and others.  The proteins implicated in these disorders are 916 
numerous (reviewed in Walker & Jucker 2015) but they all involve aggregation-prone 917 
proteins, many with prion-like domains, ability to form beta-sheet rich secondary 918 
conformations, and the ability to spread locally within brain regions and form plaques or 919 
similar deposits with concomitant toxicities.  In short, they meet the requirements set 920 
above for prion-like behavior (section 5.2) (Colby & Prusiner 2011b).  What all of these 921 
disease-causing proteins fundamentally share is that they are based on seeded aggregation 922 
of proteins.  As the field moves forward, grouping the diseases together that are caused 923 
by seeded abnormal protein aggregation is perhaps the best starting place for a new 924 
understanding of the prion concept.  What Walker and Jucker have referred to as a 925 
‘proteinaceous nucleating particle’ (Walker & Jucker 2015) brings the prion diseases and 926 
the non-prion amyloid diseases together with yet-to-be-discovered variants under the 927 
umbrella term ‘prion.’  While this term has not yet been widely used to encompass 928 
infectious and non-infectious aggregating proteins (and indeed whether the term is ever 929 
used in that fashion), the enlargement of the prion concept and the acknowledgement that 930 
there is relatively little difference between prions and non-infectious amyloids has 931 
already begun. 932 
6. Concluding Remarks 933 
In this review, I have discussed the history of the discovery of prions in mammals and the 934 
resulting recognition that previously discovered but unexplained non-Mendelian traits in 935 
the baker’s yeast Saccharomyces cerevisiae represented prions as well.  The essential 936 
genetic, biochemical, and biophysical features of the mammalian prions and amyloids, 937 
and the yeast prions and prion-like molecules, while broadly similar, show significant 938 
differences as well.  Despite this, understanding of the simple yeast prion system has 939 
allowed for major health and basic science discoveries in the mammalian context and 940 
insights from mammals have informed the studies of prion proteins in yeast.  The 941 
collective discoveries in this area have grown larger through a recognition that 942 
aggregative proteins form a larger constellation of related phenomena (including many 943 
diseases).  Because of this, the scientists and physicians studying aggregating proteins 944 
responsible for human and animal disease, whether infective or not, would do well to 945 
familiarize themselves with the literature across the whole gamut of prion, prion-like, and 946 
amyloid proteins, because these phenomena clearly demonstrate fundamental similarity at 947 
the cellular level that can be exploited to solve problems in all parts of the field. 948 
 949 
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Table 1.  Prevailing notions of natural causes of disease with notable milestones. 1933 
Time frame Agent Advocate(s) Physical Basis 
Ancient until 19th 
century 





Ancient until 19th 
century 
Contagion Fracastoro and 
others 
Direct contact with 
sick people 
1836 Living germ or seed Bassi Fungal pathogen, no 
microscopic 
evidence 
1865-1870 Microbe Pasteur Fungal pathogen 
1876 Bacterium Koch Anthrax bacillus 






1942 Virus Cohen and 
Stanley 
TMV composed of 
nucleic acid and 
protein 
20th century Slow virus Many Virus composed of 
nucleic acid and 
protein with long 
incubation period 
1982 Prion Prusiner Animal disease 
caused by protein 
only (no nucleic 
acid) 
1994 Prion Wickner Yeast infectious 
protein (no nucleic 
acid) explains 
unusual genetics of 
[PSI+], [URE3] traits 
 1934 
Table 2.  Prion diseases in non-human mammals and humans (After Colby & Prusiner 1935 
2011). 1936 
 1937 
Animal Disease Mechanism Animal(s) 
Scrapie Somatic mutation in Prnp 
gene or spontaneous 
conversion of normal PrPC 
to abnormal PrPSc or 





Infection or sporadic Cattle 
Transmissible mink 
encephalopathy (TME) 
Infection from sheep or 
cattle 
Mink 
Chronic wasting disease 
(CWD) 
Infection or possibly 
sporadic 




contaminated meat and 
bone meal (MBM) 
Ungulates (oryx, nyala, 




contaminated meat or MBM 








Human Disease Mechanism Specific Hosts 




Somatic mutation in PNRP 
gene or spontaneous 
conversion of normal PrPC 
to abnormal PrPSc 
All humans 
Familial CJD Germline mutation in PNRP 
gene 
Humans from CJD families 
Variant CJD (vCJD) Infection from consumption 
of meat from BSE cattle 
All humans 
Iatrogenic CJD (iCJD) Infection from 
contaminated medicines or 
medical equipment 
All humans 
GSS Germline mutation in PNRP 
gene 
Humans from GSS families 
Fatal Familial Insomnia 
(FFI) 
Germline mutation in PNRP 
gene 
Humans from FFI families 
Sporadic fatal insomnia 
(sFI) 
Somatic mutation in PNRP 
gene or spontaneous 
conversion of normal PrPC 
to abnormal PrPSc 
All humans 
Multiple system atrophy  Mutant alpha-synuclein 
infection in mice/cultured 
cells (artificial model) 
(reviewed in Supattapone 
2015) 
Unknown 
Other diseases Growing recognition of 
prion-like and amyloid 
proteins in disease and other 
pathological changes in 
protein conformation 
Unknown 
  1938 
Figure Legends 1939 
 1940 
Figure 1.  Brain effects of CJD, a transmissible spongiform encephalopathy, in humans.  1941 
(A) Diffusion-weighted magnetic resonance (MRI) image of a patient who presented with 1942 
a rapidly-progressive dementia, with initial hallucinations and behavioral change that 1943 
progressed to a mute, akinetic state with myoclonus. Right cortical and striatal high 1944 
signal is consistent with a diagnosis of sporadic-type Creutzfeldt-Jakob disease (sCJD).  1945 
Photo courtesy of Dr. Laughlin Dawes and Wikimedia user Filip em, 2008.  (B) 1946 
Hematoxylin-eosin stained cortex of patient with variant Creutzfeldt-Jakob (vCJD) 1947 
disease with florid plaques.  Photo is in the public domain. 1948 
Figure 2.  Process of assembly of toxic oligomers, protofilaments, and fibrils in amyloid-1949 
based diseases, including prion diseases.  (A)  Spontaneous conversion between a native 1950 
or normally-folded protein state into an abnormal or amyloid state (beta-sheet rich) are 1951 
very rare.  Both forms are stable states.  (B)  Once an abnormal amyloid form of a protein 1952 
is present in a cell, when it encounters a natively-folded protein it is capable of causing a 1953 
conformational change in which the native protein assumes an amyloid structure.  (C)  1954 
When amyloid-structured proteins encounter each other, they have a tendency to 1955 
aggregate and form, initially, short stretches of dimers, trimers, and oligomers.  Evidence 1956 
suggests these oligomers are more toxic to the cell than monomers or larger filaments 1957 
(e.g., Simoneau et al. 2007; reviewed in, e.g., Verma et al.).  (D)  Oligomers that pick up 1958 
additional monomers or oligomers may assemble into larger protofilaments and then 1959 
fibrils that can be extremely large.  These fibrils are often hallmarks of amyloidoses and 1960 
can be visualized in histopathologic sections with various straining and imaging 1961 
techniques.  Chaperones (such as Hsp104 in yeast) are capable of cleaving larger fibrils 1962 
into shorter pieces, which appears to be required for proper maintenance of the prion 1963 
during cell division.   1964 
 1965 
Figure 3.  Domain structures of canonical mammalian and fungal prions.  Repeat 1966 
domains are noted with single-letter amino acid abbreviations for repeat structures in the 1967 
protein sequences.  (A) Human Prion Protein (PrP), which can interconvert between 1968 
normal PrPC and abnormal PrPSc protein variants.  Abbreviations:  SP, signal peptide; S-1969 
S, disulfide bridge; GPI, Glycophosphatidylinositol anchor.  (B) Yeast prion protein 1970 
Sup35 (eRF3) which can give rise to the [PSI+] prion.  Abbreviations:  N-domain, prion 1971 
domain; ND, nucleation domain region of the N-domain; ORD, oligopeptide repeat 1972 
domain region of the N-domain; M domain, middle domain; C domain, catalytic domain.  1973 
 1974 
Figure 4.  Assay for presence of the yeast [PSI+] prion using the ade2-1 mutant nonsense 1975 
suppression (eRF3) function of Sup35.  (A) Schematic diagram for ade2-1 generation of 1976 
color phenotypes in the presence or absence of the [PSI+] prion. (B) Examples of 1977 
red/white color selection using the ade2-1 assay.  Left, mutant forms of Sup35 that are 1978 
[PSI+] in this assay are compared with the control wild-type [PSI+] prion, plus or minus 1979 
curing with guanidine hydrochloride (GdHCl).  Right, mutant forms of Sup35 that are 1980 
[psi-] (non-prion) are shown. 1981 
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